Biofrontera vs Pelthos Therapeutics
Biofrontera is the larger business, with $41.7m of revenue in fiscal 2025 against $16.8m for Pelthos Therapeutics (2.5 times as much). Biofrontera kept more of each dollar of sales as profit: a net margin of -25.3% against -257.9%.
| Latest fiscal year | BiofronteraBFRI, 2025 | Pelthos TherapeuticsPTHS, 2025 |
|---|---|---|
| Revenue | $41.7m | $16.8m |
| Revenue growth | 11.7% | — |
| Net income | −$10.5m | −$43.3m |
| Operating margin | — | -193.1% |
| Net margin | -25.3% | -257.9% |
| Return on equity | -141.3% | — |
| Free cash flow | −$13.4m | −$22.7m |
| Cash | $6.4m | $18.0m |
| Total debt | $0 | $31.4m |
| Debt to equity | — | 80.9% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | $0 |
| Employees | 92 | 92 |
| Market value | $12.5m | $39.1m |
| Price vs our value range | — | — |
| Moat score | — | — |
| Insider trades, 12 months | 0 buys, 0 sales | 2 buys, 24 sales |